Clinical Medicine Insights: Oncology

Management Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T?

Submit a Paper

Clinical Medicine Insights: Oncology 2011:5 325-332

Consise Review

Published on 20 Oct 2011

DOI: 10.4137/CMO.S5977

Further metadata provided in PDF

Sign up for email alerts to receive notifications of new articles published in Clinical Medicine Insights: Oncology

The Editor-in-Chief has endorsed this article

Therapeutic advances changed dramatically in 2010 with the U.S. FDA approval of the autologous cellular immunotherapy sipuleucel-T for the treatment of men with asymptomatic or minimally symptomatic metastatic CRPC. This is an updated review on the data regarding therapeutic options with particular focus on the emerging strategies for incorporating sipuleucel-T into this changing landscape.

Post a Comment

x close

Discussion Add A Comment
No comments yet...Be the first to comment.

What Your Colleagues Say About Clinical Medicine Insights: Oncology
Publishing in  “Clinical Medicine Insights: Oncology” was one of my best experience so far in an academic context. I found the process of going through submission, review, editing, and publication to be quite easy and most importantly, fair and efficient. I congratulate the team at Libertas Academica for a very well managed journal.
Dr E.I. Efremidou (Assistant Professor in Surgery, Medical School, Democritus University of Thrace, Hellas)
More Testimonials

Quick Links

New article and journal news notification services